BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 17503040)

  • 1. Current approaches in dendritic cell generation and future implications for cancer immunotherapy.
    Tuyaerts S; Aerts JL; Corthals J; Neyns B; Heirman C; Breckpot K; Thielemans K; Bonehill A
    Cancer Immunol Immunother; 2007 Oct; 56(10):1513-37. PubMed ID: 17503040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell-based immunotherapy.
    Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK
    Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell preparation for immunotherapeutic interventions.
    Simon T; Fonteneau JF; Grégoire M
    Immunotherapy; 2009 Mar; 1(2):289-302. PubMed ID: 20635946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.
    Bol KF; Schreibelt G; Rabold K; Wculek SK; Schwarze JK; Dzionek A; Teijeira A; Kandalaft LE; Romero P; Coukos G; Neyns B; Sancho D; Melero I; de Vries IJM
    J Immunother Cancer; 2019 Apr; 7(1):109. PubMed ID: 30999964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
    H Yi D; Appel S
    Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cells in cancer immunotherapy.
    Schuler G
    Eur J Immunol; 2010 Aug; 40(8):2123-30. PubMed ID: 20853498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic dendritic cell-based cancer vaccines: the state of the art.
    Strioga MM; Felzmann T; Powell DJ; Ostapenko V; Dobrovolskiene NT; Matuskova M; Michalek J; Schijns VE
    Crit Rev Immunol; 2013; 33(6):489-547. PubMed ID: 24266347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic Cells and Cancer Immunity.
    Gardner A; Ruffell B
    Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
    Shurin MR; Gregory M; Morris JC; Malyguine AM
    Expert Opin Biol Ther; 2010 Nov; 10(11):1539-53. PubMed ID: 20955111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic Cell-Based Cancer Vaccines.
    Santos PM; Butterfield LH
    J Immunol; 2018 Jan; 200(2):443-449. PubMed ID: 29311386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy.
    Shu S; Zheng R; Lee WT; Cohen PA
    Crit Rev Immunol; 2007; 27(5):463-83. PubMed ID: 18197808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquisition and Presentation of Tumor Antigens by Dendritic Cells.
    Bonaccorsi I; Campana S; Morandi B; Ferlazzo G
    Crit Rev Immunol; 2015; 35(5):349-64. PubMed ID: 26853848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of dendritic cells in cancer immunotherapy.
    Schuler G; Schuler-Thurner B; Steinman RM
    Curr Opin Immunol; 2003 Apr; 15(2):138-47. PubMed ID: 12633662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Active immunotherapy of prostate cancer with a focus on dendritic cells].
    Thomas-Kaskel AK; Veelken H
    Actas Urol Esp; 2007 Jun; 31(6):668-79. PubMed ID: 17896564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.
    Bol KF; Schreibelt G; Gerritsen WR; de Vries IJ; Figdor CG
    Clin Cancer Res; 2016 Apr; 22(8):1897-906. PubMed ID: 27084743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
    Reardon DA; Mitchell DA
    Semin Immunopathol; 2017 Feb; 39(2):225-239. PubMed ID: 28138787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of dendritic cell-based vaccines for cancer therapy.
    Reinhard G; Märten A; Kiske SM; Feil F; Bieber T; Schmidt-Wolf IG
    Br J Cancer; 2002 May; 86(10):1529-33. PubMed ID: 12085199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell vaccines in melanoma: from promise to proof?
    Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
    Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
    Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
    Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current state and perspectives of dendritic cell vaccination in cancer immunotherapy.
    Farkas A; Conrad C; Tonel G; Borbenyi Z; Kemeny L; Dobozy A; Nestle FO
    Skin Pharmacol Physiol; 2006; 19(3):124-31. PubMed ID: 16612139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.